Resources from the same session
1595MO - Phenotypic and genomic characterization of de novo metastatic prostate cancer: An ancillary study of the PEACE-1 phase III trial
Presenter: Cedric Pobel
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA68 - Efficacy and safety of darolutamide plus androgen-deprivation therapy (ADT) in patients with metastatic hormone-sensitive prostate cancer (mHSPC) from the phase III ARANOTE trial
Presenter: Fred Saad
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA69 - Prostate cancer efficacy results from a randomised phase III evaluation of transdermal oestradiol (tE2) versus luteinising hormone releasing hormone agonists (LHRHa) for androgen suppression in non-metastatic (M0) prostate cancer
Presenter: Ruth Langley
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1595MO, LBA68 and LBA69
Presenter: Niven Mehra
Session: Mini oral session: GU tumours, prostate
Resources:
Slides
Webcast
LBA70 - Adding metformin to androgen deprivation therapy (ADT) for patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC): Overall survival (OS) results from the multi-arm, multi-stage randomised platform trial STAMPEDE
Presenter: Silke Gillessen
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA71 - Open-label, multicentre randomised trial of Radium223-docetaxel versus docetaxel-Radium223 sequence in metastatic castration resistant prostate cancer (mCRPC) with prospective biomarker evaluation (RAPSON study)
Presenter: Vincenza Conteduca
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
1597MO - Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Dana Rathkopf
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
LBA72 - Nivolumab 3mg/kg and ipilimumab 1mg/kg (nivo3/ipi1) in molecularly selected patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Niven Mehra
Session: Mini oral session: GU tumours, prostate
Resources:
Abstract
Slides
Webcast
Invited Discussant 1597MO and LBA72
Presenter: Christopher Sweeney
Session: Mini oral session: GU tumours, prostate
Resources:
Slides
Webcast